Vaxcyte Inc at Guggenheim Vaccine and Infectious Disease Conference (Virtual) Transcript
So thanks, everybody, for joining us. And this is our 2nd Annual Vaccines and Infectious Diseases Day. We were joined last year by Vaxcyte, so I just want to thank the team for joining us again. Many of you know me, I'm Seamus Fernandez, Guggenheim's global pharma analyst. And with us again this year is Vaxcyte. Many of you know Vaxcyte is a vaccine company with a unique platform that enables the development of vaccines to prevent some of the most common infectious diseases. Their lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine to prevent invasive pneumococcal disease. Many of you know that this is a $6 billion-plus global market, so there is certainly a lot of interest and enthusiasm for this space. I'm going to hand it over to CEO and Founder, Grant Pickering, for opening remarks and introductions to the rest of the team with us today. So, Grant, over to you.
Thank you, Seamus. Let me just start by saying thank you very much for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
